674 related articles for article (PubMed ID: 31836877)
21. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
Okines AF
Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy.
Molinelli C; Parisi F; Razeti MG; Arecco L; Cosso M; Fregatti P; Del Mastro L; Poggio F; Lambertini M
Expert Rev Anticancer Ther; 2021 Mar; 21(3):241-250. PubMed ID: 33245671
[No Abstract] [Full Text] [Related]
23. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
24. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
Hassett MJ; Li H; Burstein HJ; Punglia RS
Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
[TBL] [Abstract][Full Text] [Related]
26. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
27. Current and future anti-HER2 therapy in breast cancer.
Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
[TBL] [Abstract][Full Text] [Related]
28. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Harbeck N
Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480
[TBL] [Abstract][Full Text] [Related]
29. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Ahmed S; Sami A; Xiang J
Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
[TBL] [Abstract][Full Text] [Related]
30. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.
Di Cosimo S; Triulzi T; Pizzamiglio S; De Cecco L; de Azambuja E; Fumagalli D; Putzai L; Harbeck N; Izquierdo M; Peña L; Daidone MG; Huober J; Gori S; Cinieri S; Torri V; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Tagliabue E
Eur J Cancer; 2019 Sep; 118():1-9. PubMed ID: 31284184
[TBL] [Abstract][Full Text] [Related]
31. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
32. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Nuciforo PG; Aura C; Holmes E; Prudkin L; Jimenez J; Martinez P; Ameels H; de la Peña L; Ellis C; Eidtmann H; Piccart-Gebhart MJ; Scaltriti M; Baselga J
Ann Oncol; 2015 Jul; 26(7):1494-500. PubMed ID: 25851628
[TBL] [Abstract][Full Text] [Related]
33. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
[TBL] [Abstract][Full Text] [Related]
35. HER2-positive breast cancer: Current and new therapeutic strategies.
Escrivá-de-Romaní S; Arumí M; Bellet M; Saura C
Breast; 2018 Jun; 39():80-88. PubMed ID: 29631097
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
[TBL] [Abstract][Full Text] [Related]
37. The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.
Waks AG; Tolaney SM
Future Oncol; 2015; 11(24):3261-71. PubMed ID: 26634944
[TBL] [Abstract][Full Text] [Related]
38. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.
Brandão M; Pondé NF; Poggio F; Kotecki N; Salis M; Lambertini M; de Azambuja E
Expert Rev Anticancer Ther; 2018 Jul; 18(7):629-649. PubMed ID: 29781317
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
40. Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .
Zardavas D; Cameron D; Krop I; Piccart M
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
